Data gathered: November 27
AI Stock Analysis - Aldeyra Therapeutics (ALDX)
Analysis generated November 12, 2024. Powered by Chat GPT.
Aldeyra Therapeutics, Inc. is a biotechnology company focused on the development of treatments for immune-mediated diseases. With a portfolio that primarily targets various inflammatory diseases, Aldeyra leverages its proprietary technologies to develop therapies that address unmet medical needs. The company's core pipeline includes candidates for conditions such as dry eye disease, allergic conjunctivitis, and autoimmune diseases. Aldeyra's mission is to bring innovative and effective treatments to the market, improving patients' quality of life.
Stock Alerts - Aldeyra Therapeutics (ALDX)
 |
Aldeyra Therapeutics | November 19 Price is up by 5.5% in the last 24h. |
|
Aldeyra Therapeutics | November 18 Price is up by 17.3% in the last 24h. |
|
Aldeyra Therapeutics | November 13 Price is down by -6.4% in the last 24h. |
|
Aldeyra Therapeutics | November 12 Price is down by -5.5% in the last 24h. |
Alternative Data for Aldeyra Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 100 | Sign up | Sign up | Sign up |
| Google Trends | 13 | Sign up | Sign up | Sign up |
| Patents | 48 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 824 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,827 | Sign up | Sign up | Sign up |
| Twitter Followers | 469 | Sign up | Sign up | Sign up |
| Twitter Mentions | 37 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 17 | Sign up | Sign up | Sign up |
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.
| Price | $4.94 |
| Target Price | Sign up |
| Volume | 215,150 |
| Market Cap | $296M |
| Year Range | $2.88 - $6.32 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
What is Leerink Partnrs’ Forecast for ALDX FY2024 Earnings?November 18 - ETF Daily News |
 |
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug ReproxalapNovember 18 - Yahoo |
|
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 7.9% in OctoberNovember 18 - ETF Daily News |
Aldeyra Therapeutics Shares Up, FDA to Review New Drug ApplicationNovember 17 - Finnhub |
|
 |
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option AgreementNovember 17 - Yahoo |
Aldeyra Therapeutics : Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement Form 8 KNovember 17 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 3.7M | -3.7M | -15M | 0 | -0.250 |
| Q2 '24 | 0 | 3M | -3.5M | -17M | -18M | -0.280 |
| Q1 '24 | 0 | 3.2M | -3.7M | -8.1M | -9.3M | -0.140 |
| Q4 '23 | 390,000 | 1.8M | -2.3M | -4.7M | -6M | -0.080 |
| Q3 '23 | 0 | 2.6M | -3.1M | -8.2M | -7.6M | -0.140 |
Insider Transactions View All
| Greenberg Bruce filed to sell 126,382 shares at $4.7. August 14 '24 |
| Machatha Stephen filed to sell 236,771 shares at $4.7. August 14 '24 |
| EDELMAN JOSEPH filed to buy 9,275,851 shares at $4.7. April 8 '24 |
| EDELMAN JOSEPH filed to buy 9,238,139 shares at $4.7. April 8 '24 |
| EDELMAN JOSEPH filed to buy 9,097,858 shares at $4.1. April 3 '24 |
Similar companies
Read more about Aldeyra Therapeutics (ALDX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Aldeyra Therapeutics?
The Market Cap of Aldeyra Therapeutics is $296M.
What is the current stock price of Aldeyra Therapeutics?
Currently, the price of one share of Aldeyra Therapeutics stock is $4.94.
How can I analyze the ALDX stock price chart for investment decisions?
The ALDX stock price chart above provides a comprehensive visual representation of Aldeyra Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Aldeyra Therapeutics shares. Our platform offers an up-to-date ALDX stock price chart, along with technical data analysis and alternative data insights.
Does ALDX offer dividends to its shareholders?
As of our latest update, Aldeyra Therapeutics (ALDX) does not offer dividends to its shareholders. Investors interested in Aldeyra Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Aldeyra Therapeutics?
Some of the similar stocks of Aldeyra Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.